title: Antiplatelet drugs and generation of thrombin in clotting blood.
abstract: Platelets participate in formation of thrombin through secretion of coagulation factors and by providing a catalytic surface on which prothrombinase complex is assembled. We studied the effects of four antiplatelet drugs on thrombin formation in healthy volunteers. Thrombin generation was monitored both in vitro--in recalcified plasma--and ex vivo--in blood emerging from a standardized skin microvasculature injury, which also served to determine bleeding time. A mathematical model has been developed to describe the latter reaction. It is based on estimation of the rate of increase in fibrinopeptide A (FPA), a specific marker of thrombin activity, in blood emerging from skin incisions. Two hours after the ingestion of 500 mg of aspirin, thrombin formation became significantly impaired both in vitro and ex vivo. In contrast, 2 hours after the oral administration of placebo, indomethacin 50 mg, or OKY-046 (a thromboxane synthase inhibitor) 400 mg, thrombinogenesis remained unaltered. Ticlopidine, studied either 3 hours after 500 mg oral administration, or after 5 days of intake at a daily dose of 500 mg, had no effect on thrombin generation. Thus, aspirin, contrary to other antiplatelet drugs, depresses thrombin formation in clotting blood, a phenomenon that might be of clinical relevance. It is suggested that aspirin exerts this effect by acetylating prothrombin and/or macromolecules of platelet membrane.
authors.affiliation: Department of Medicine, Copernicus Academy of Medicine, Cracow, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Szczeklik
authors.forename: M
authors.initials: M
authors.lastname: Krzanowski
authors.forename: P
authors.initials: P
authors.lastname: Góra
authors.forename: J
authors.initials: J
authors.lastname: Radwan
mesh_terms: D000328:Adult; D001241:Aspirin / Q000494:pharmacology; D001777:Blood Coagulation / Q000502:physiology*; D005260:Female; D005344:Fibrinopeptide A / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008433:Mathematics; D008689:Methacrylates / Q000494:pharmacology; D008875:Middle Aged; D008954:Models, Biological; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D012867:Skin / Q000098:blood supply / Q000293:injuries; D013917:Thrombin / Q000378:metabolism*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D013988:Ticlopidine / Q000494:pharmacology
chemical_list: D008689:Methacrylates; D010975:Platelet Aggregation Inhibitors; D005344:Fibrinopeptide A; D013917:Thrombin; D013930:Thromboxane-A Synthase; C034364:ozagrel; D013988:Ticlopidine; D001241:Aspirin; D007213:Indomethacin